Even as the executive order President Trump issued last month on artificial intelligence furthered the conversation about a developing national strategy for the sector, it was met with certain criticism. A common complaint was that the plan won’t implement itself.
“The... Read more »
Austin—All politics is local, the adage goes, and those campaigns are sorely stuck in analog mode.
That’s why Shion Deysarkar co-founded Blue Squad two years ago as a “digital coalition” to support progressive candidates by providing them with greater access... Read more »
Two months after insisting on Twitter that he wasn’t going anywhere, Food and Drug Administration Commissioner Scott Gottlieb announced his resignation today. He leaves a record of health and medical regulation that was more active than critics who spoke out... Read more »
Tasso, a Seattle-based startup that is developing an at-home blood sample collection device, announced Tuesday it has raised $6.1 million from investors. The new money will support its effort to launch sales of the device, Tasso OnDemand, in the coming... Read more »
People in the Pacific Northwest who grow plants in greenhouses and nurseries face good odds of turning a profit on their 2019 harvests, according to Spokane, WA-based Northwest Farm Credit Services, which supports farmers, ranchers, and other agribusiness in the... Read more »
One size fits most (at best), and a women’s sizing system created during the Depression doesn’t gibe in an e-commerce business that prizes personalization.
That’s why startups are turning to new technologies like 3D scanning and machine learning software to produce... Read more »
Privacy issues continued to boil to the surface in February. In part, it’s a reflection of the long tail of consequences that began in early 2018 when the broader public learned that Facebook had shared data from millions of user profiles... Read more »
After years of boom times, the U.S. biopharmaceutical industry is dealing with unprecedented threats on several fronts: public backlash against high drug prices, slowing sales, and the possibility of more government regulation.
In this Xconomy Special Report, our veteran biotech journalists... Read more »
Could a shareholder revolt doom the planned marriage of Bristol-Myers Squibb and Celgene? Analysts have hinted at the possibility since the two companies shook hands in January, but the threat became real this week.
Bristol (NYSE: BMY) and Celgene... Read more »